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S U M M A R Y
Objectives: We conducted a retrospective study on the impact of the empiric use of linezolid on mortality
in vancomycin-resistant Enterococcus spp (VRE)-colonized hematology and hematopoietic stem cell
transplantation (HSCT) patients.
Methods: VRE-colonized inpatients for whom complete data were available (n = 100) were divided into
two groups: those who received empiric linezolid in the course of fever refractory to broad-spectrum
antibiotics, replacing the glycopeptide utilized for the previous 48 h, and those who did not (control
group). All patients were followed until hospital discharge or death. The impact of linezolid and risk
factors for all-cause mortality were evaluated; variables with p < 0.10 were analyzed in a multivariate
model. A Kaplan–Meier survival analysis was done to compare survival among febrile patients colonized
by VRE who received empiric linezolid with patients who did not receive linezolid.
Results: Patients empirically prescribed linezolid were generally younger (median age 33 vs. 44 years;
p = 0.008) and more likely to be recipients of an allogeneic HSCT (24 (68.6%) vs. 24 (36.9%); p = 0.009)
than patients who did not receive the drug. Fourteen (21.5%) VRE bloodstream infections were
diagnosed, all in patients who did not receive empiric linezolid (p = 0.002). In-hospital mortality was
comparable in empiric linezolid and non-linezolid users (19 (54.3%) vs. 27 (41.5%), respectively;
p = 0.293). The Kaplan–Meier survival analysis showed no signiﬁcant difference in survival comparing
the group that received linezolid to the group that did not (p = 0.72). Graft-versus-host disease (GVHD;
odds ratio (OR) 5.90, 95% conﬁdence interval (CI) 1.46–23.79; p = 0.012) and persistence of neutropenia
(OR 6.93, 95% CI 1.72–27.94; p = 0.0065) were independent predictors of all-cause in-hospital death in
HSCT patients, and persistence of neutropenia in non-HSCT patients (OR 8.12, 95% CI 1.22–53.8;
p = 0.030).
Conclusions: The empiric use of linezolid in VRE-colonized hematology patients had no impact on
mortality, which appeared rather to be associated with the persistence of neutropenia in general and
GVHD in the HSCT group.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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Vancomycin-resistant Enterococcus spp (VRE) infections in
hematology and hematopoietic stem cell transplant (HSCT)
patients have been gaining attention given the overall increasingciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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and the high morbidity and mortality in this patient population.4
Colonization of the gastrointestinal tract with VRE is postulated to
precede VRE infection.5–9 Bloodstream infection (BSI) due to VRE,
in particular, has been linked to increased mortality in this
population.10–14 VRE-attributable mortality, however, is difﬁcult
to ascertain due to the severity of illness of the underlying disease
in these patients.15–17
Anti-VRE antibiotic drugs have reportedly been advocated as
empirical agents for the treatment of febrile neutropenia among
VRE-colonized patients,6,18,19 even though data supporting their
empirical use in this setting are largely lacking. Resistance to
linezolid among VRE, on the other hand, has been reported,20–22
and is directly associated with its consumption,22 thus warranting
the investigation of this approach to ensure an adequate rationale
for the empiric use of linezolid in VRE-colonized patients.
A retrospective study of the impact of empiric use of linezolid
and risk factors for all-cause mortality in hematology and HSCT
patients colonized by VRE was performed.
2. Methods
2.1. Design
This retrospective study was performed to assess the outcomes
of the empiric use of linezolid (Pﬁzer, NY, USA), prescribed in
accordance with the literature recommendations (adult patients,
600 mg intravenous (IV) every 12 h; pediatric patients, 10 mg/kg
IV every 8 h), in the course of persistent febrile episodes in
hematology and HSCT adult and pediatric patients admitted to the
Hematology and Bone Marrow Transplant wards of the Hospital
das Clı´nicas da Universidade de Sa˜o Paulo (Sao Paulo, Brazil). VRE-
colonized patients admitted between January 2005 and May
2007 were considered eligible. Complete paper charts and
electronic records holding microbiological data were necessary
for inclusion in the study; these were available for 100 patients. A
case series describing baseline characteristics and outcomes of
VRE-colonized patients receiving linezolid empirically and
patients who did not receive this antibiotic (considered the
control group) was recorded; risk factors associated with in-
hospital mortality were evaluated. The study was approved by the
institutional research ethics board (CAPPesq – Ethics Commission
for the Analyses of Research Projects, Hospital das Clı´nicas da
Universidade de Sa˜o Paulo).
2.2. Setting
The study was conducted in a 900-bed tertiary-care teaching
hospital in Sao Paulo, Brazil, encompassing a joint unit with eight
bone marrow transplant and 15 hematology beds. Local protocols
for the treatment of febrile neutropenia in place at the time were
largely based on the 1997 guidelines of the Infectious Diseases
Society of America (IDSA)23 and did not advocate the routine use of
anti-VRE drugs in VRE-colonized patients. Infectious diseases
specialists restrict access to linezolid through an individual case
assessment as part of the institutional antimicrobial stewardship
program. During the study period, the empiric use of linezolid
was considered on a case-basis for VRE-colonized patients upon
persistence of fever after 48 h of use of broad Gram-negative bacilli
antibiotic coverage and a glycopeptide antibiotic. Whenever
linezolid was prescribed, glycopeptide antibiotics were immedi-
ately discontinued. Antibiotic therapy was de-escalated and
optimized according to microbiological data and was continued
for the standard recommended duration according to the site of
infection, or for that recommended in the absence of conﬁrmed
infection. Discontinuation of antimicrobial therapy, in the absenceof isolation of a causative agent, was contingent on completing a
minimum of 5 days of treatment and on resolution of fever and
recovery of neutrophil counts for 72 h (absolute neutrophil counts
(ANC) >0.5  109 cells/l). Specimens for microbiological diagnosis
were collected routinely prior to administration or upon changes in
antimicrobial therapy.
2.3. Data collection
Microbiological data and infection control and medical records
were reviewed by three investigators (BGM, LFL, SFC). Infections
were deﬁned according to the Centers for Disease Control and
Prevention nosocomial infection criteria.24 The following variables
were compared between the case and control groups: age, length
of hospital stay, underlying hematological disease, type of HSCT,
the presence of mucositis or graft-versus-host disease (GVHD) as
diagnosed by the assisting hematologist and recorded on the
patient’s chart, Multinational Association of Supportive Care in
Cancer (MASCC) risk index score,26 use of a central venous catheter
(CVC), site of infection, laboratory tests including ANC and platelet
counts, duration and severity of neutropenia, and linezolid
prescription information. The patients were followed from hospital
admission until the ﬁrst of the following events: in-hospital death
or discharge from the hospital.
2.4. VRE surveillance
VRE rectal/peri-anal screening swabs were taken routinely
upon admission and were repeated weekly, until colonization was
documented or until hospital discharge. Surveillance cultures were
seeded directly in VRE-selective medium containing 6 mg/ml of
vancomycin. Identiﬁcation and susceptibility testing, including
ampicillin and linezolid susceptibility testing, were performed for
all specimens using automated (Vitek; bioMe´rieux, Hazelwood,
MO, USA) and/or disk diffusion methods, the latter following the
methodology established by the Clinical and Laboratory Standards
Institute (CLSI).
2.5. Statistical analysis
Data analyses were performed using PASW Statistics 18 (SPSS
Inc., Chicago, IL, USA). The two-tailed Fisher’s exact test was used
for categorical variables and the Mann–Whitney U-test was used
for continuous variables. Logistic regression models were devel-
oped to identify factors independently associated with in-hospital
mortality. All non-overlapping variables with p < 0.1 on univariate
analysis and that ﬁtted a biological rationale were entered into the
model in a single step. The logistic regression model obtained was
also applied for subgroup analysis (non-HSCT vs. HSCT). A p-value
<0.05 was considered to be statistically signiﬁcant. A Kaplan–
Meier survival analysis was done to compare survival among
febrile hematology and HSCT patients colonized by VRE who




A total of 1535 patients were admitted to the hematology
and bone marrow transplant wards during the study period. VRE
are endemic to these medical units; the period studied was
delimited to exclude VRE outbreaks, and no linezolid-resistant
strains were observed during the study period. The median
length of hospitalization prior to VRE colonization was 10 days
(range 0–61 days).
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Demographic and clinical characteristics of the patients are
shown in Table 1. Patients empirically prescribed with linezolid
(total of 35 patients) were generally younger (median age 33 vs.
44 years; p = 0.008) and more likely to be recipients of allogeneic
HSCT (24 (68.6%) vs. 24 (36.9%) patients; p = 0.009) than patients
who did not receive this drug (total of 65 patients). GVHD was
similarly distributed in both groups – nine (25.7%) in the linezolid
group and nine (13.9%) in the non-linezolid group (p = 0.175) – and
affected the following sites: the skin in six patients (33%), the
gastrointestinal tract in ﬁve (28%), the lungs in two (11%), and the
liver in two (11%). No patients receiving linezolid empirically
developed VRE infections (all of these patients had cultures
collected prior to their ﬁrst dose which remained negative).
Fourteen patients (14%) in the control group developed a ﬁrst
episode of BSI due to VRE, justifying the targeted use of linezolid. Of
these, 13 episodes were caused by Enterococcus faecium and one by
Enterococcus faecalis, with all isolates – including E. faecalis – also
resistant to ampicillin on disk diffusion testing and microdilution
method. An additional ﬁve patients in the control group received
linezolid for other indications (three urinary and two respiratory
tract infections with VRE as the only isolate).
Patients receiving linezolid empirically had a lower predicted
mortality at hospital admission (median MASCC risk index score
21 in cases vs. 16 in controls; p = 0.021). All-cause in-hospital
mortality, nonetheless, was statistically similar in the two groups:
54.3% (n = 19) in the empiric linezolid group vs. 41.5% (n = 27) in
the non-linezolid group (p = 0.293) (Table 1).
Neutropenia at admission and persistent neutropenia (ANC
<0.5  109/l at hospital discharge/death) were seen in similar
proportions, whereas severe neutropenia during hospital stayTable 1
Clinical and demographic characteristics of hematology and HSCT patients colonized wit
prescriptiona
Variables Emp
Age, years, median (range) 33 (
Sex, female, n (%) 18 (
E. faecium colonization, n (%) 25 (
Time to VRE colonization, days, median (range) 10 (
Underlying disease, n (%)
Acute leukemia 17 (
Chronic leukemia 4 (
Aplastic anemia 1 (
Fanconi anemia 2 (
Non-Hodgkin lymphoma 7 (
Hodgkin lymphoma 0 
Multiple myeloma 2 (
Myelodysplastic syndrome 0 
Other 2 (
HSCT, n (%) 28 (
Allogeneic 24 (
Autologous 4 (
GVHD, n (%) 9 (
Mucositis, n (%) 6 (
Central venous catheter, n (%) 33 (
ANC at admission, 109/l, median (range) 0.9
ANC at discharge/death, 109/l, median (range) 1.8
Neutropenia at admission (neutrophils <0.5 109/l, n (%) 14 (
Severe neutropenia during hospital stay (neutrophils <0.1 109/l), n (%) 6 (
Persistent neutropenia (neutrophils <0.5  109/l), n (%) 13 (
Platelets at admission, 109/l, median (range) 30 (
Platelets at discharge/death, 109/l, median (range) 32 (
VRE BSI, n (%) 0 
MASCC at admission, median (range) 21 (
Length of stay, days, median (range) 29 (
In-hospital mortality, n (%) 19 (
HSCT, hematopoietic stem cell transplant; GVHD, graft-versus-host disease; ANC, absolut
Supportive Care in Cancer risk index score.
a Fisher’s exact test was used for comparisons of categorical variables and the Mann(ANC <0.1  109/l) was less commonly observed among those in
the empiric linezolid group (n = 6, 17%) than in the non-linezolid
group (n = 24, 36.9%) (p = 0.043) (Table 2).
The empiric use of linezolid had no impact on the overall
mortality (odds ratio (OR) 1.67, 95% conﬁdence interval (CI) 0.73–
3.82; p = 0.293) (Table 2). The Kaplan–Meier survival analysis
showed no signiﬁcant difference in survival between hematology
and HSCT febrile patients colonized by VRE who received empiric
linezolid and those who did not (p = 0.72) (Figure 1). In a logistic
regression model, the risk factors independently associated with
death were the presence of GVHD (OR 3.69, 95% CI 1.13–12.04;
p = 0.030) and persistent neutropenia (OR 6.46, 95% CI 2.20–19.10;
p = 0.0007). When mortality was assessed exclusively in recipients
of allogeneic HSCT using the model that included GVHD, ANC at
admission, platelets at admission, Hodgkin lymphoma present
only in patients undergoing HSCT, and persistent neutropenia, the
following were conﬁrmed as independent predictors of death:
GVHD (OR 5.90, 95% CI 1.46–23.79; p = 0.012) and persistent
neutropenia (OR 6.93, 95% CI 1.72–27.94; p = 0.0065). The
regression model without GVHD and Hodgkin lymphoma applied
to non-HSCT patients suggested persistent neutropenia as the only
independent predictor of in-hospital mortality (OR 8.12, 95% CI
1.22–53.85; p = 0.030).
4. Discussion
The importance of VRE colonization to guide the empiric use
of antibiotics in febrile neutropenia remains a matter of
debate.7,15–17,25,27 The 2010 IDSA guidelines for the use of
antimicrobial agents in neutropenic patients with cancer recom-
mend considering the initial use of linezolid or daptomycin for
febrile neutropenic VRE-colonized patients treated in hospitalsh vancomycin-resistant Enterococcus spp (VRE) according to the pattern of linezolid
iric use of linezolid (n = 35) No use of linezolid (n = 65) p-Value
2–67) 44 (1–77) 0.008
51.4) 24 (36.9) 0.204
71.4) 51 (78.5) 0.468
0–46) 8 (0–61) 0.893
48.6) 31 (47.7) 1.000
11.4) 2 (3.1) 0.180
2.9) 4 (6.2) 0.655
5.7) 0 0.120
20.0) 12 (18.5) 1.000
5 (7.7) 0.159
5.7) 5 (7.7) 1.000
4 (6.2) 0.295
5.7) 2 (3.1) 0.610
80.0) 34 (52.3) 0.009
68.6) 24 (36.9) 0.003
11.4) 10 (15.4) 0.765
25.7) 9 (13.8) 0.175
17.1) 17 (26.2) 0.455
94.3) 61 (93.8) 1.000
 (0–21.1) 1.1 (0–19.1) 0.781
 (0–34.4) 2.1 (0–127) 0.544
40.0) 29 (44.6) 0.678
17.1) 24 (36.9) 0.043
37.1) 17 (26.2) 0.263
1–144) 28 (1–546) 0.951
3–218) 33 (2–624) 0.624
14 (21.5) 0.002
10–23) 16 (0–23) 0.021
3–99) 27 (4–134) 0.416
54.3) 27 (41.5) 0.293
e neutrophil count; BSI, bloodstream infection; MASCC, Multinational Association of
–Whitney U-test was used for comparisons of continuous variables.
Table 2
Risk factors associated with mortality among 100 hematology and HSCT patients colonized by vancomycin-resistant Enterococcus spp (VRE)a
Variables Died (n = 46) Survived (n = 54) Univariate analysis Multivariate analysis
OR (95% CI) p-Value OR (95% CI) p-Value
Age, years, median (range) 44 (3–77) 34 (1–66) 0.105
Sex, female, n (%) 23 (50.0) 19 (35.2) 1.84 (0.82–4.11) 0.158
E. faecium colonization, n (%) 33 (71.7) 43 (79.6) 0.65 (0.26–1.63) 0.482
Underlying diseases, n
Acute leukemia 21 27 0.84 (0.38–1.85) 0.692
Chronic leukemia 4 2 2.48 (0.43–14.18) 0.410
Aplastic anemia 3 2 1.81 (0.29–11.36) 0.659
Fanconi anemia 1 1 1.18 (0.07–19.37) 1.000
Non-Hodgkin lymphoma 9 10 1.07 (0.39–2.91) 1.000
Hodgkin lymphoma 0 5 0.060
Multiple myeloma 2 5 0.44 (0.08–2.41) 0.447
Myelodysplastic syndrome 3 1 3.70 (0.37–36.83) 0.331
Other 3 1 3.70 (0.37–36.83) 0.331
HSCT, n (%) 30 (65.2) 32 (59.3) 1.29 (0.57–2.91) 0.680
Allogeneic 26 (56.5) 22 (40.7) 1.89 (0.85–4.19) 0.160
Autologous 4 (8.7) 10 (18.5) 0.42 (0.12–1.44) 0.247
GVHD, n (%) 12 (26.1) 6 (11.1) 2.82 (0.96–8.26) 0.069 3.69 (1.13–12.04) 0.030
Mucositis, n (%) 12 (26.1) 11 (20.4) 1.38 (0.54–3.51) 0.634
Central venous catheter, n (%) 43 (93.5) 51 (94.4) 0.84 (0.16–4.39) 1.000
ANC at admission, 109/l, median (range) 0.535 (0–16) 2.35 (0–21.1) 0.099 0.51
Neutropenia at admission (neutrophils <0.5  109/l), n (%) 22 (47.8) 21 (38.9) 1.44 (0.65–3.194) 0.421
Severe neutropenia (neutrophils <0.1  109/l), n (%) 16 (34.8) 14 (25.9) 1.52 (0.64–3.60) 0.385
Persistent neutropenia (neutrophils <0.5  109/l), n (%) 23 (50) 7 (13.0) 6.71 (2.51–17.93) <0.001 6.46 (2.20–19.10) 0.007
Platelets at admission, 109/l, median (range) 23 (1–546) 31 (1–436) 0.044 0.914
VRE BSI, n (%) 8 (17.4) 6 (11.1) 1.68 (0.53–5.27) 0.400
Empiric use of linezolid, n (%) 19 (41.3) 16 (29.6) 1.67 (0.73–3.82) 0.293
Length of stay, days, median (range) 32 (3–134) 27 (6–110) 0.478
MASCC at admission, median (range) 16.5 (8–23) 21 (0–23) 0.306
HSCT, hematopoietic stem cell transplant; OR, odds ratio; CI, conﬁdence interval; GVHD, graft-versus-host disease; ANC, absolute neutrophil count; BSI, bloodstream
infection; MASCC, Multinational Association of Supportive Care in Cancer risk index score.
a Fisher’s exact test was used for comparisons of categorical variables and the Mann–Whitney U-test was used for comparisons of continuous variables. Non-overlapping
variables with p < 0.1 in the univariate analysis ﬁtting a biological rationale were included in the binary logistic regression model.
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condition is unstable or if the patient has positive blood culture
results suspicious for VRE.28 Our study, however, suggests that the
empiric use of linezolid in febrile hematology and HSCT patients
colonized by VRE does not have an impact on mortality. MoreFigure 1. Kaplan–Meier analysis comparing the survival of 100 febrile hematology and H
red line represents the patients who did not receive linezolid and the green line patieimportantly, it indicates that persistent neutropenia is a risk factor
for mortality for both HSCT and non-HSCT patients, and that GVHD is
a relevant factor associated with mortality in VRE-colonized HSCT
patients. Thus, the use of empiric linezolid in colonized VRE
neutropenic patients should be rethought and further studies withSCT patients colonized by VRE who received or did not receive empiric linezolid. The
nts who received linezolid.
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of linezolid in this situation.
This study has several limitations. The design was retrospective,
it included a small number of patients with a short duration of
follow-up, and may express the local data; however, it appears that
the use of empiric linezolid in febrile hematology and HSCT
patients should be reconsidered and conﬁrmed by controlled
studies.
Although, the linezolid group did not develop VRE BSI, our data
do not support a clear association of VRE BSI with increased
mortality. Thus, it seems that VRE infections, which were treated
with linezolid, were likely markers of the overall severity of illness
in the patients with microbiologically conﬁrmed infections. In this
regard, available evidence suggests that short courses of linezolid
have an acceptable safety proﬁle regarding myelotoxicity,33-35 and
comparable, if not superior survival in VRE BSI when compared to
other VRE-active agents.34-35
Clinical studies have shown that colonization is an important
risk factor for BSI among hematology patients.19,29 The dysregula-
tion of innate immune defenses through broad-spectrum antibi-
otic use, and the consequent depletion of commensal bacteria,
seems to play a key role.30 In an animal model, colonization by VRE
was signiﬁcantly higher after a course of antibiotics; interestingly,
this phenomenon was prevented by stimulation of the innate
immune receptor, toll-like receptor 5 (TLR5), through systemic
administration of ﬂagellin, a structural component of Gram-
negative bacteria.31 A shift in the intestinal microﬂora towards an
Enterococcus-predominant microbiota was documented in asso-
ciation with antibiotic use and preceded the occurrence of VRE BSI
in HSCT recipients.5,8 As transplant patients typically have more
intensive antimicrobial exposure, this may account for the high
rates of VRE colonization in HSCT patients seen in our study.
Previous reports have found an association between VRE BSI
and decreased survival,10–13,32 leading to some advocating empiric
VRE therapy during periods of fever and neutropenia in colonized
hematology patients.4,6,19 Conﬂicting data, however, have failed to
support this association, suggesting that VRE infection is simply a
marker of a poor prognosis.16,17 Although retrospective, our data
corroborate the latter, showing that despite the patients who did
not receive empiric linezolid therapy having lower MASCC scores,
being sicker, and developing VRE BSI, the mortality was similar in
the two groups and that the crude mortality was independently
associated with GVHD in HSCT patients and with persistent
neutropenia in both HSCT and non-HSCT patients. These indepen-
dent risk factors are markers of severity of illness in the patients
and have previously been associated with bacterial infection and
mortality in this type of patient.36,37
Although, none of the isolates in the present study was resistant
to linezolid, resistance to linezolid among VRE has been
reported,20–22 and the spread of resistance is a concern worldwide;
this reinforces the importance of the rational use of linezolid in
neutropenic patients.
In conclusion, the empiric use of linezolid in the course of
refractory fever based on the data observed in this study would
unlikely modify the in-hospital mortality of VRE-colonized
hematology and HSCT patients, which rather seems to be
associated with GVHD and the persistence of neutropenia.
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